Logo-bi
Editorial

1. Why BioImpacts?
Mohammad-Reza Rashidi*
Bioimpacts. 2011;1(1): 1-2. doi: 10.5681/bi.2011.001
PMCID: PMC3648949     PMID: 23678401     Scopus ID: 84876717709    
Article
PDF
XML
Cited By:
1
1
0
Editorial

2. Integration of Molecular, Cellular and Translational Researches in BioImpacts
Yadollah Omidi* ORCID
Bioimpacts. 2011;1(1): 3-5. doi: 10.5681/bi.2011.002
PMCID: PMC3648944     PMID: 23678402     Scopus ID: 84876732629    
Article
PDF
XML
Cited By:
1
1
0
Editorial

3. To impact or not to impact, this is not a question for BioImpacts!
Mohammad A. Rafi*
Bioimpacts. 2015;5(1): 1-2. doi: 10.15171/bi.2015.11
PMCID: PMC4401162     PMID: 25901290     Scopus ID: 84924864123    
Article
PDF
XML
Cited By:
2
2
1
Editorial

4. BioImpacts: An emerging global journal
Roghaiyeh Ilghami ORCID, Hafez Mohammadhasanzadeh ORCID, Jaleh Barar ORCID, Mohammad A. Rafi* ORCID
Bioimpacts. 2020;10(4): 207-208. doi: 10.34172/bi.2020.26
PMCID: PMC7502912     PMID: 32983935     Scopus ID: 85092069314    
Article
PDF
Full Text
XML
Cited By:
1
1
0
Mohammad Rafi received his PhD in Animal Biology from the University of Montpellier, France, in 1970. Though he has worked on several lysosomal storage diseases, his main research interest is gene therapy of neurodegenerative disorders using animal models of globoid cell leukodystrophy (Krabbe disease). With successful AAVrh10-mediated treatment of murine and canine models, his research is moving towards the treatment trials of human patients.

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge